Drug profile · INN
etelcalcetide
PARSABIV
etelcalcetide (PARSABIV) is a calcium sensing receptor agonist. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — etelcalcetide
- US status
- approved
- Class
- Systemic hormonal preparations (H05)
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
etelcalcetide (PARSABIV) is a calcium sensing receptor agonist. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Calcium sensing receptor agonist
Primary target: Extracellular calcium-sensing receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is etelcalcetide?
etelcalcetide (PARSABIV) is a calcium sensing receptor agonist. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for etelcalcetide?
PARSABIV is a marketed brand name for etelcalcetide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of etelcalcetide?
etelcalcetide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.